Vera Therapeutics Inc [VERA] stock is trading at $47.34, up 15.21%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VERA shares have gain 15.77% over the last week, with a monthly amount glided 8.98%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on January 25, 2024, and set its price target to $26. On January 08, 2024, Cantor Fitzgerald initiated with a Overweight rating. Raymond James started tracking the stock assigning a Outperform rating and suggested a price target of $29 on December 18, 2023. Jefferies upgraded its rating to a Buy and raised its price target to $26 on November 10, 2023. Guggenheim started tracking with a Buy rating for this stock on August 16, 2023, and assigned it a price target of $27. In a note dated January 04, 2023, Wedbush downgraded an Neutral rating on this stock and revised its target price from $33 to $8.
Vera Therapeutics Inc [VERA] stock has fluctuated between $9.68 and $50.78 over the past year. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Vera Therapeutics Inc [NASDAQ: VERA] shares were valued at $47.34 at the most recent close of the market. An investor can expect a potential drop of -45.08% based on the average VERA price forecast.
Analyzing the VERA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.48 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.19 points at the first support level, and at 43.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 49.74, and for the 2nd resistance point, it is at 52.15.
Ratios To Look Out For
For context, Vera Therapeutics Inc’s Current Ratio is 21.15. As well, the Quick Ratio is 21.15, while the Cash Ratio is 1.36.
Transactions by insiders
Recent insider trading involved BETH C SEIDENBERG, Director, that happened on Oct 28 ’24 when 15000.0 shares were purchased. PRESIDENT AND CEO, Fordyce Marshall completed a deal on Oct 23 ’24 to sell 19375.0 shares. Meanwhile, Director MARSHALL FORDYCE bought 19375.0 shares on Oct 23 ’24.
